3-0-demethyl fortimicin A: in vitro activity and interpretive zone standards for disk diffusion susceptibility tests.
The in vitro activity of 3-0-demethyl fortimicin A was compared to that of amikacin and tobramycin against 5,230 clinical isolates in four institutions. Amikacin and tobramycin were more active than 3-0-demethyl fortimicin A against Pseudomonas aeruginosa and Acinetobacter spp., but all three drugs had similar activity against the Enterobacteriaceae and Staphylococcus aureus. Additional tests with 335 representative gram-negative bacilli compared five different aminoglycosides, demonstrating differences with some isolates. Standardized disk diffusion tests were also performed with 30 micrograms 3-0-demethyl fortimicin A disks, according to the National Committee for Clinical Laboratory Standards. The following interpretive breakpoints are proposed: less than or equal to 11 mm for resistant (MIC greater than or equal to 32 micrograms/ml) and greater than or equal to 15 mm for susceptible (MIC less than or equal to 16 micrograms/ml).
D000150:Acinetobacter / Q000187:drug effects; D000583:Amikacin / Q000494:pharmacology; D000617:Aminoglycosides / Q000494:pharmacology; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects*; D004352:Drug Resistance, Microbial; D004755:Enterobacteriaceae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D013211:Staphylococcus aureus / Q000187:drug effects; D013291:Streptococcus / Q000187:drug effects; D014031:Tobramycin / Q000494:pharmacology
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; C027445:3-O-demethylfortimicin A; D000583:Amikacin; D014031:Tobramycin